Kafocin

NDA 50219, held by Lilly. Cephaloglycin.

As of Nov 13, 2026, NDA 50219 (Kafocin), held by Lilly, was first approved by FDA on Jun 12, 1970, with 0 approved supplements and 0 published complete response letters.

• First approved: Jun 12, 1970
• Supplements approved: 0
• Complete response letters: 0

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters